Generated by AI
Seres Therapeutics Inc. is a clinical-stage biotechnology company focused on developing live biotherapeutics that modulate the human microbiome. The company’s current portfolio centers on oral microbiome-based therapies designed to address serious diseases in areas such as gastrointestinal disorders, immune-mediated conditions, and infection prevention. Its pipeline includes investigational programs aimed at restoring healthy microbial balance and improving disease-relevant functions in the gut. Seres Therapeutics serves a specialized role in the biopharmaceutical market by advancing novel treatments for medically vulnerable patient populations, with development efforts centered on microbiome therapeutics rather than traditional small-molecule or antibody drugs. Headquartered in Cambridge, Massachusetts, Seres Therapeutics is positioned within the broader biotechnology sector as a developer of targeted live biotherapeutic products.
Website101 Cambridgepark Drive
Cambridge, MA, 02140
United States
The latest articles about MCRB.
Summary of Nov 18's posts. Generated by AI.
Summary of Jul 14's posts. Generated by AI.
Summary of Jul 17's posts. Generated by AI.
Summary of Jun 5's posts. Generated by AI.
Investors talking about MCRB also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.